POOJA BARDHAN
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology MARIETTA, GA NPI 1962601344
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology GA Acerta Pharma LLC All categories
General Payments — all program years on this page
$2,061.26
- Category: General Payments
- Program years: PY2018–2024
- Record count: 89
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,091.94 across 45 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,091.94 | 45 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $124.23 | 5 |
| Merck Sharp & Dohme Corporation | $84.30 | 3 |
| PFIZER INC. | $63.63 | 3 |
| Janssen Biotech, Inc. | $58.78 | 3 |
| Lilly USA, LLC | $56.42 | 2 |
| GlaxoSmithKline, LLC. | $55.88 | 2 |
| ABBVIE INC. | $48.44 | 2 |
| Exelixis Inc. | $45.74 | 2 |
| Acrotech Biopharma Inc. | $44.03 | 2 |
| Daiichi Sankyo Inc. | $43.98 | 2 |
| Regeneron Healthcare Solutions, Inc. | $33.37 | 1 |
| Alexion Pharmaceuticals, Inc. | $32.52 | 1 |
| TerSera Therapeutics LLC | $32.02 | 1 |
| PharmaEssentia USA Corporation | $30.78 | 1 |
| BeiGene USA, Inc. | $29.22 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $28.43 | 1 |
| Dendreon Pharmaceuticals LLC | $25.27 | 1 |
| EISAI INC. | $24.71 | 1 |
| Fennec Pharmaceuticals, Inc. | $24.63 | 1 |
| SHIELD THERAPEUTICS INC | $23.87 | 1 |
| Stemline Therapeutics Inc. | $22.68 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $22.15 | 1 |
| Genentech USA, Inc. | $21.56 | 1 |
| Coherus Biosciences Inc. | $21.45 | 1 |
| Mirati Therapeutics, Inc. | $20.57 | 1 |
| Novocure Inc. | $19.52 | 1 |
| E.R. Squibb & Sons, L.L.C. | $18.34 | 1 |
| GENZYME CORPORATION | $18.32 | 1 |
| ARRAY BIOPHARMA INC | $17.10 | 1 |
By program year
Records — PY2024 (45)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.